In Vitro & In Vivo Diagnostic Substances · SIC 2835

ACHIEVE LIFE SCIENCES, INC.

ACHV

Watch

Latest revenue

as of

Latest net income

as of

Net margin

as of

Price · 5Y

-10.2% / yr 23.9 pts / yr vs S&P 500 41.4% total
Compare:

Live market

delayed ≤15 min
$4.69
1.96%
Market cap
$481.5M
Enterprise value
$481.5M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$6.15
52-wk low
$2.00
Beta
Shares out
102.7M

5-year trend

About ACHV

Business description and risk factors will appear here once ACHV's latest filing is fully ingested.

Profitability

Return on equity

-261.5%

37.2%

Return on assets

-130.8%

26.8%

Leverage

Debt / equity

1.00×

17.8%

Debt / assets

50.0%

8.9%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$-10.2M+20.7%

Q4 2025

2025-12-31

$-14.7M-18.6%

Q3 2025

2025-09-30

$-14.4M-15.4%

Q2 2025

2025-06-30

$-12.7M-50.3%

Q1 2025

2025-03-31

$-12.8M-97.5%

Q4 2024

2024-12-31

$-12.4M

Q3 2024

2024-09-30

$-12.5M-76.0%

Q2 2024

2024-06-30

$-8.5M-2.7%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

In Vitro & In Vivo Diagnostic Substances · SIC 2835

No data yet for industry average

Your notes

Keep private notes on ACHV — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$0

Insider selling

$1.1M

Net activity

−$1.1M

Distinct insiders

6

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2025-09-18

Mark K Oki

Chief Financial Officer

Sale50,060$2.92$146.2K
2025-09-18

Richard Alistair Stewart

Chief Executive Officer

Sale129,501$2.92$378.1K
2025-09-04

Jerry Wan

Principal Accounting Officer

Sale14,070$2.77$39.0K
2025-09-04

Thomas Braxton King

Director

Sale139,858$2.77$387.4K
2025-09-04

Cindy Jacobs

President & CMO

Sale27,629$2.77$76.5K
2025-09-04

Jaime Xinos

Chief Commercial Officer

Sale20,854$2.77$57.8K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns ACHV

Institutional value

$32.4M

Total shares held

11.0M

Distinct holders

40

-37 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1FRANKLIN RESOURCES INC4.4M$12.8M+0 (+0.0%)No change
2VANGUARD CAPITAL MANAGEMENT LLC2.2M$6.5MNew
3Simplify Asset Management Inc.1.2M$3.5M+0 (+0.0%)No change
4LPL Financial LLC728.4K$2.1M+95.3K (+15.1%)Added
5KVP Capital Advisors, LP462.4K$1.4M+0 (+0.0%)No change
6BlackRock, Inc.439.4K$1.3M+20.2K (+4.8%)Added
7UBS Group AG326.3K$959.2K+41.0K (+14.4%)Added
8VANGUARD FIDUCIARY TRUST CO316.2K$929.6KNew
9JANE STREET GROUP, LLC176.6K$519.2K-205.6K (-53.8%)Trimmed
10Lakeside Advisors, INC.111.1K$326.6KNew
11WELLS FARGO & COMPANY/MN102.0K$299.8K+31.9K (+45.6%)Added
12Blue Trust, Inc.85.9K$252.5K+0 (+0.0%)No change
13Hudson Bay Capital Management LP84.9K$249.6K+17.2K (+25.5%)Added
14MANCHESTER FINANCIAL INC66.2K$194.7K+7.1K (+12.1%)Added
15DIMENSIONAL FUND ADVISORS LP52.4K$154.1K+0 (+0.0%)No change
16MEMBERS WEALTH LLC30.0K$126.9K+0 (+0.0%)No change
17Next Capital Management LLC35.0K$102.9K+18.9K (+117.0%)Added
18BCV Asset Management Inc.26.4K$77.5KNew
19Goldstone Financial Group, LLC24.2K$71.0K+0 (+0.0%)No change
20Vanguard Global Advisers, LLC22.6K$66.5KNew

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once ACHV's latest filing finishes processing.